The first hints proving the role of PTEN in trastuzumab resistance came in 2004 when Nagata and colleagues observed activation of PTEN upon trastuzumab treatment and showed that PTEN is required for the anti-tumor efficacy of trastuzumab, since its inhibition is sufficient to induce resistance [182]. The gene discussed is PTEN; the disease is neoplasm.